Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks IPOs and placings
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
London pre-open: Stocks seen weaker after Friday's surge
(Sharecast News) - London stocks were set to fall at the open on Monday, having closed at their highest level in more than a year on Friday. The FTSE 100 was called to open around 20 points lower.
There are no macroeconomic releases of note due in the UK.
In corporate news, B&Q owner Kingfisher said it expected lower annual profits in the current year as the home improvement market continued to lag behind demand for housing.
The company, which also owns the Brico depot chain in France, said it expects adjusted pre-tax profit of £490m - £550m compared with the £568m it reported for last year, down 25% on 2022/23.
Direct Line said it was confident in its standalone prospects after Belgium's Ageas said late on Friday that it would not be making an offer for the London-listed insurer.
Ageas said that following two recent attempts to engage with the company's board about a possible offer, both of which were rejected, it will not make an offer for Direct Line.
Direct Line said in a brief statement: "As communicated at Direct Line Group's 2023 preliminary results on 21 March 2024, the board believes under Adam Winslow's leadership the company is well-positioned to drive material improvement in performance that is expected to unlock significant value for Direct Line Group shareholders."
Wise announced the appointment of Emmanuel Thomassin as its new chief financial officer and director, effective from 1 October, succeeding Matthew Briers who announced his departure last year.
The London-listed consumer currency specialist said Thomassin had extensive experience from his tenure as CFO at Delivery Hero. Until he assumes his role, Kingsley Kemish, currently senior group financial director, would serve as interim CFO.
AstraZeneca announced that its autoimmune disease treatment Ultomiris has been given the green light by US regulators.
The drug, which is also approved for certain patients in Japan and the EU, is to be used for the treatment of adult patients with anti-aquaporin-4, antibody-positive neuromyelitis optica spectrum disorder (NMOSD), a disease that affects the central nervous system including the spine and optic nerves.
The positive ruling by the US Food and Drug Administration followed positive results from the recent Champion-NMOSD phase III trial, which showed zero relapses over a median treatment duration of 73 weeks.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity and Inclusion | Doing Business with Fidelity | Fidelity gender pay report | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Security | Statutory and Regulatory disclosures | Whistleblowing policy
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.